Trial News & Events

13th Annual NEALS Meeting

This year's annual NEALS meeting took place October 22nd-24th in Clearwater Beach, FL.

Cytokinetics provides update on Tirasemtiv

Cytokinetics, Inc announced that it has completed its review of results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv ALS) and has concluded that the effects observed on Slow Vital Capacity (SVC) in PALS treated with tirasemtiv are potentially clinically meaningful. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Click here to read more about this update.…

Genervon Phase IIa Study of GM604 Completed

Genervon Biopharmaceuticals, LLC announced that it has completed the analysis of its Phase 2a double blinded, randomized, placebo controlled clinical trials of Amyotrophic Lateral Sclerosis (NCT01854294) and Parkinson’s disease (NCT 01850381) for its drug candidate GM604. "The two trials were designed to determine whether a six-dose treatment of GM6 would begin the process of disease modification. Genervon was told not to expect any statistically significant drug effects because of the small number of patients in both trials, but was delighted to find that both clinical and biomarker data in the ALS and the PD…

Phase II Mexiletine Study Completed

A phase II, 60 patient NEALS-sponsored multicenter randomized controlled trial of Mexiletine in the treatment of ALS was recently completed. 

NEALS Sites Continue to Participate in ALS Ice Bucket Challenge

The ALS Ice Bucket Challenge, started by PALS and Boston native Pete Frates, has been steadily raising awareness for the disease and encouraging donations for ALS research since its inception in the summer of 2014. Over the last few months, participation in the ALS #icebucketchallenge has gone viral on social media. The challenge has seen millions of people dump a bucket of ice water on their head and then nominate three others to either do the same or to donate money to the cause. NEALS and the ALS Multidisciplinary Clinic at Mass General Hospital completed the challenge and nominated three other NEALS sites (Drexel, SUNY Upstate, and Johns Hopkins) to do the same, encouraging those sites to then challenge other NEALS sites. Over 50 NEALS sites around the US and Canada have completed the challenge to date. Please consider a donation to the NEALS Consortium by clicking here.

Medicinova to Initiate Clinical Trial of MN-166

Medicinova, Inc announced the FDA approval to initiate a clinical trial of MN-166 (ibudilast) ALS. The principal investigator of the study is Benjamin Rix Brooks, MD, of Carolinas Neuromuscular/ALS-MDA Center in Charlotte, NC. Read the full press release here.…